The FDA's drug approvals database records a supplement approved on 13 October to an abbreviated new drug application (ANDA 207490) for a generic buprenorphine product held by Strides Pharma.
The public record does not say what the supplement changed. Supplements to generic applications usually cover labelling updates to match the reference product, manufacturing or packaging changes; they are not new indications and are not safety findings in themselves.
For prescribers, nothing changes today. If a labelling change has been made, it will normally mirror the reference product's label, which is the place to check for current dosing and safety wording.
- FDA approved a supplement to a generic buprenorphine application on 13 October
- The public record does not state the content of the change
- Generic supplements are usually labelling or manufacturing updates, not new indications
- Check the reference product label for current dosing and safety information
Why it matters
Reading regulatory entries correctly stops administrative actions being mistaken for safety signals.
Don't overread it
A licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free